Acute respiratory tract infections area major public health concern. High-risk patients with T cell deficiencies, including hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients, individuals older than 65 and younger than five years old, as well as other individuals whose immune systems are suppressed, face a range of serious consequences when faced with these common respiratory infections, including: pneumonia, hospitalizations, respiratory failure, and death.
ALVR106 has the potential to transform the treatment of respiratory viruses and substantially reduce the severity of viral respiratory infections while improving patient outcomes.
Acute respiratory tract infections due to community-acquired respiratory viruses such as RSV, Influenza, PIV, and hMPV are a major public health concern.
Respiratory tract infections due to influenza, RSV, PIV, and hMPV are found in up to 40 percent of allogeneic HSCT recipients. For approximately half of these HSCT patients, these viral infections progress from less serious upper tract respiratory infections, with symptoms similar to those of a common cold, to far more serious lower respiratory tract infections with severe symptoms including pneumonia and bronchiolitis and are associated with increased mortality up to 20-45%.
There are limited or no treatment options available for these respiratory viruses.
In vitro data demonstrates that ALVR106 reactive cells have antiviral activity against each of the targeted viruses with minimal or no activity against non-virus-infected cells. This preclinical data supports the potential for antiviral benefit and safety of ALVR106 when administered to patients.
The preclinical data was published in the journal, Haematologica in 2019.